Clinical Trial Update: A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study of ASP8273 in patients with non-small cell lung cancer harboring EGFR mutations has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ASP8273

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Non-Small-Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor Mutations | Phase 1 | Status: COMPLETED